Skip to main
NDRA
NDRA logo

NDRA Stock Forecast & Price Target

NDRA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ENDRA Life Sciences Inc is poised for growth due to its innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which could significantly improve the diagnosis and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in over one billion individuals globally. The anticipated FDA approval within the next year is expected to boost investor sentiment and enhance stock value, reflecting a robust net present value (NPV) analysis that suggests considerable potential upside. Furthermore, TAEUS promises cost-effective and precise capabilities compared to current diagnostic tools, which could capture a substantial market share within the healthcare sector.

Bears say

ENDRA Life Sciences Inc. reported a net loss of $1.6 million, equating to an earnings per share (EPS) of $(2.10), which exceeded previous estimates of $(1.95). The company also experienced another loss of $1.2 million, with an EPS of $(1.71), aligning with prior estimates but indicating persistent financial challenges. Furthermore, significant risks impacting the stock's outlook include liquidity concerns, potential failures in clinical efficacy and regulatory approval, difficulties in commercialization, and the pressing competition within the biotech and medtech sectors.

NDRA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ENDRA Life Sciences (NDRA) Forecast

Analysts have given NDRA a Strong Buy based on their latest research and market trends.

According to 1 analysts, NDRA has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ENDRA Life Sciences (NDRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.